The shares of Traws Pharma (NASDAQ:GRASS) soared 24% in after-market trading Friday on encouraging results from a Phase 1 study of the company’s drug Tivoxavir Marboxil in the treatment of H5N1 bird flu.
The study showed a single dose of
The shares of Traws Pharma (NASDAQ:GRASS) soared 24% in after-market trading Friday on encouraging results from a Phase 1 study of the company’s drug Tivoxavir Marboxil in the treatment of H5N1 bird flu.
The study showed a single dose of
New York, New York–(Newsfile Corp. – January 10, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of PACS Group Inc. (NYSE: PACS) of (i)…
Palantir Technologies (NASDAQ: PLTR) The stock’s impressive 372% rise in 2024 has made the stock extremely expensive, which explains why investors may be wary of buying this high-flying artificial intelligence…